Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians.

Area of Science:

• Dermatology
• Immunology

Background:

• Dupilumab is a monoclonal antibody used to treat inflammatory conditions.
• Dupilumab facial redness (DFR) is an emerging adverse effect characterized by eczematous rash on the face and neck.
• DFR prevalence ranges from 4% to 43.8% in dupilumab users, affecting both children and adults.

Purpose of the Study:

• To review the pathogenesis and clinical presentation of DFR.
• To outline diagnostic approaches for DFR.
• To present management strategies for DFR.

Main Methods:

• Literature review of case reports and studies on DFR.
• Analysis of diagnostic methods including skin scraping, serologies, biopsy, and patch testing.
• Evaluation of management options from conservative measures to drug interruption.

Main Results:

• DFR is a recognized side effect of dupilumab therapy.
• A range of diagnostic tools can aid in identifying DFR.
• Management strategies are varied, with potential for symptom resolution.

Conclusions:

• Clinicians need to be aware of DFR as a potential side effect of dupilumab.
• Systematic diagnostic evaluation is crucial for appropriate management.
• Tailored treatment plans, including allergen avoidance or dupilumab adjustment, can effectively manage DFR.